LOESTRIN FE 1/20 Drug Patent Profile
✉ Email this page to a colleague
When do Loestrin Fe 1/20 patents expire, and what generic alternatives are available?
Loestrin Fe 1/20 is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in LOESTRIN FE 1/20 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOESTRIN FE 1/20?
- What are the global sales for LOESTRIN FE 1/20?
- What is Average Wholesale Price for LOESTRIN FE 1/20?
Summary for LOESTRIN FE 1/20
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 7 |
Patent Applications: | 130 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LOESTRIN FE 1/20 at DailyMed |
![LOESTRIN FE 1/20 drug patent expirations Drug patent expirations by year for LOESTRIN FE 1/20](/p/graph/s/t/LOESTRIN_FE_1/20-patent-expirations.png)
Recent Clinical Trials for LOESTRIN FE 1/20
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Purdue Pharma LP | Phase 1 |
Eisai Inc. | Phase 1 |
US Patents and Regulatory Information for LOESTRIN FE 1/20
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | LOESTRIN FE 1/20 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 017354-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |